RYTM Rhythm Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-08 14:29
Why RYTM matters now
Rhythm Pharmaceuticals, Inc. (RYTM) is a US stock in Healthcare. The latest InvestLog snapshot shows $113.23 with -1.07% on the session and $7.77B in market capitalization; recent performance reads 1-month +10.98% and YTD -9.58%.
The latest financial table shown here is Q1 2026, with revenue of $60.1M, net income of $-55.6M, and EPS of $-0.83. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.8%.
The latest indexable market news headline is "Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $143.00; recent insider activity includes Smith Hunter C filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
53.53
P/S
30.57
EV/EBITDA
-37.64
DCF Value
$-381.41
FCF Yield
-1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.4%
Operating Margin
-90.9%
Net Margin
-93.3%
ROE
-203.2%
ROA
-45.8%
ROIC
-56.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $60.1M | $-55.6M | $-0.83 |
| Q4 2025 | $57.3M | $-47.5M | $-0.73 |
| FY 2025 | $189.8M | $-196.5M | $-3.11 |
| Q3 2025 | $51.3M | $-52.9M | $-0.82 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$139.57
Target (Median)
$143.00
Target Range
$125.00 - $155.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.92
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.